Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.
Case Number:
24-2351
Court:
Nature of Suit:
830 Patent Infringement (Fed. Qst.)
Companies
- Amgen Inc.
- Biocon Ltd.
- Regeneron Pharmaceuticals Inc.
- Samsung Electronics Co. Ltd.
- Sandoz International GmbH
- Viatris Inc.
Sectors & Industries:
-
January 14, 2025
Fed. Circ. Judge Asks What's The Rush In Eylea Biosimilar Case
Counsel for Amgen and a Federal Circuit judge got into a back-and-forth Tuesday concerning the pace of an appeal over a denied injunction on Regeneron's biosimilar of Eylea, with the judge wondering why the attorney was so eager to move things along.
-
January 09, 2025
IP Forecast: OpenAI, Microsoft Look To Toss NYT Case
OpenAI and its backers at Microsoft will try persuading a New York judge to dismiss one of the major copyright suits against them, with arguments that using news stories to train the startup's artificial intelligence model is a "transformative" use. Here's a spotlight on where that case stands — plus all the other major intellectual property matters on deck in the coming week.